Impact of disease-modifying therapy on β-cell function and metabolic control in newly diagnosed type 1 diabetes
- PMID: 37931635
- DOI: 10.1016/S2213-8587(23)00299-1
Impact of disease-modifying therapy on β-cell function and metabolic control in newly diagnosed type 1 diabetes
Conflict of interest statement
I declare no competing interests.
Comment on
-
C-peptide and metabolic outcomes in trials of disease modifying therapy in new-onset type 1 diabetes: an individual participant meta-analysis.Lancet Diabetes Endocrinol. 2023 Dec;11(12):915-925. doi: 10.1016/S2213-8587(23)00267-X. Epub 2023 Nov 3. Lancet Diabetes Endocrinol. 2023. PMID: 37931637
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
